FOLD - Amicus Therapeutics, Inc.

Amicus Therapeutics, Inc. is a biotechnology firm dedicated to the discovery, development, and delivery of medical treatments for rare conditions. Its primary commercial offering is Galafold, an orally administered precision medicine designed for adult patients with a confirmed diagnosis of Fabry disease, specifically those exhibiting an amenable galactosidase alpha gene variant as identified by in vitro assay data.

Sector

Healthcare

Industry

Biotechnology

Market Cap

$4.55B

Beta

0.48

52-Week Range

5.51-14.5

CEO

Bradley L. Campbell

Employees

499

IPO Date

May 31, 2007

Exchange

NASDAQ

FOLD Options Snapshot

Options pricing data for FOLD is refreshed daily after the close. When listed contracts exist, this page surfaces the latest at-the-money implied volatility, max pain strike, dealer gamma exposure (GEX), and 25-delta skew. Listed contracts and live snapshots appear once the options chain has been published by the exchange for the most recent session.

What This Page Covers

The FOLD overview links into per-metric analysis views: max pain, gamma exposure, volatility skew, expected move, options chain, open interest history, and aggregate Greeks. Microstructure data is available on short interest, short volume, fail-to-deliver, and market structure. Corporate data is on fundamentals, earnings, analyst ratings, and insider trading.